Delving into the Latest Updates on Cystemix-1 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

The University of New South Wales

Active Organization-

Inactive Organization

The University of New South Wales

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The objective of this study is to determine the dose response relationship regarding blood loss, PK, PD and clinical outcomes of MDCO-2010 in comparison to placebo and tranexamic acid in patients undergoing primary cardiac surgery with cardiopulmonary bypass. The aim of the study is to define minimally effective dose of MDCO-2010.

Start Date01 Mar 2012

Sponsor / Collaborator

The Medicines Co.

100 Clinical Results associated with Cystemix-1

Login to view more data

100 Translational Medicine associated with Cystemix-1

Login to view more data

100 Patents (Medical) associated with Cystemix-1

Login to view more data

100 Deals associated with Cystemix-1

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	-	The University of New South Wales	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01530399 (CTgov)	Phase 2	Hemorrhage	44	MDCO 1 (MDCO 1)	qflhvmexul(iotsglsghq) = zxglqxjzha mdmuxtobxt (nrlafyymxb, rsrurbdiqo - gtzaeezgsg) View more	-	10 Dec 2015
				MDCO 2 (MDCO 2)	qflhvmexul(iotsglsghq) = gzjsvprrcu mdmuxtobxt (nrlafyymxb, rheiavojel - zcdynjivla) View more